Trastuzumab-containing regimens for metastatic breast cancer
Trastuzumab has been recognised as an effective therapy for women with HER2 positive breast cancer for several years, and a Cochrane Review on the effects for women with early stage disease was published in 2012. This was joined in June 2014 by a review of the drug’s effects for more advanced cancer. Sara Balduzzi from the University of Modena and Reggio Emilia in Italy describes these findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - June 13, 2014 Category: Journals (General) Authors: The Cochrane Collaboration Tags: Issue 4 to 6, April to June 2014 Source Type: podcasts
Trastuzumab containing regimens for metastatic breast cancer
Trastuzumab has been recognised as an effective therapy for women with HER2 positive breast cancer for several years, and a Cochrane Review on the effects for women with early stage disease was published in 2012. This was joined in June 2014 by a review of the drug’s effects for more advanced cancer. Sara Balduzzi from the University of Modena and Reggio Emilia in Italy describes these findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - June 1, 2014 Category: Journals (General) Authors: Cochrane Source Type: podcasts
Michael F. Press, MD, PhD - Best Practices in HER2 Testing for Breast Cancer
Best Practices in HER2 Testing for Breast Cancer (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - February 4, 2014 Category: Cancer & Oncology Authors: Answers in CME Tags: Science, Medicine Source Type: podcasts
Finally! Data in Low-Risk HER2 Breast Cancer
Drs. Kathy Miller and Ian Krop talk about why a single-arm study in low-risk cancer is a huge advance for a population of understudied breast cancer patients. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - December 24, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts
Finally! Data in Low-Risk HER2 Breast Cancer
Drs. Kathy Miller and Ian Krop talk about why a single-arm study in low-risk cancer is a huge advance for a population of understudied breast cancer patients. (Source: Medscape Oncology)
Source: Medscape Oncology - December 24, 2013 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Finally! Data in Low-Risk HER2 Breast Cancer
Drs. Kathy Miller and Ian Krop talk about why a single-arm study in low-risk cancer is a huge advance for a population of understudied breast cancer patients. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - December 24, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts
SABCS 2013: Therapy for HER2+ Breast Cancer
Drs. Eric Winer, Stephen Sener, William Gradishar, and Joyce O'Shaugnessey comprise the faculty for this compelling group of Best of the Day interviews with Dr. Kristy Russell as moderator. These inte...
Author: imedex
Added: 12/12/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 12, 2013 Category: Cancer & Oncology Source Type: podcasts
Obesity and HER2 Breast Cancer
(Source: Mayo Clinic - Medical Edge Radio)
Source: Mayo Clinic - Medical Edge Radio - October 16, 2013 Category: Consumer Health Advice Authors: Mayo Clinic Source Type: podcasts
TH3RESA Trial Update - Dr. Sunil Verma
Dr. Sunil Verma with updates from ECC 2013 on the study of trastuzumab emtansine in comparison with treatment of physician's choice in patients with her2-positive breast cancer who have received at le...
Author: oncologyeducation
Added: 10/07/2013 (Source: Oncology Tube)
Source: Oncology Tube - October 7, 2013 Category: Cancer & Oncology Source Type: podcasts
HER2 Metastatic Breast Cancer Treatment
In this clip, Dr. David A. Margileth discusses the recent advances in treatment options for HER2 metastatic breast cancer patients and the various instances in which they may be used. He also goes on ...
Author: feeds
Added: 09/05/2013 (Source: Oncology Tube)
Source: Oncology Tube - September 5, 2013 Category: Cancer & Oncology Source Type: podcasts
ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab
Eight-year follow-up data from the HERA trial confirm that one-year of adjuvant trastuzumab (Herceptin) is better than 2 years -- or none in HER2-positive breast cancer. Bruce Jancin of IMNG Medical ...
Author: feeds
Added: 09/04/2013 (Source: Oncology Tube)
Source: Oncology Tube - September 4, 2013 Category: Cancer & Oncology Source Type: podcasts
Listen to The Lancet: 18 July
Richard Gelber discusses results of the HERA trial comparing 2 years vs 1 year trastuzumab for HER2 positive breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - July 18, 2013 Category: Journals (General) Authors: The Lancet Source Type: podcasts
The Lancet: July 18, 2013
Richard Gelber discusses results of the HERA trial comparing 2 years vs 1 year trastuzumab for HER2 positive breast cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - July 18, 2013 Category: Journals (General) Authors: The Lancet Source Type: podcasts
